Progressive solutions for less invasive treatment of structural heart disease
Less invasive cardiothoracic surgery is a safe, effective alternative to open-heart surgery, which means there is no need to cut through the breastbone and spread the ribs to access the heart
It has many clear benefits, including less scarring and reduced pain thanks to smaller incisions, compared with open-heart surgery which requires a long incision down the centre of the chest; creating faster recovery times, less blood loss, and a lower risk of infection.
Those benefits have been recognised and harnessed by Glasgow-based MedTech company CardioPrecision with three out of four cardiac centres in Scotland now using its innovative technology.
CardioPrecision
A 2007 spinout of InnoScot Health, NHS Greater Glasgow and Clyde, and the Golden Jubilee National Hospital, CardioPrecision is a global leader in innovative approaches to treatment of structural heart disease and cardiothoracic interventions.
Its patented technology allows chest cavity surgery to be performed through a short incision in the skin crease of the neck and could potentially be applied to a wide range of cardiothoracic procedures.
With its proven range of CoreVista® devices and accessories, the company has taken major steps into the high value US market, achieved domestic success with its technologies adopted by 75% of cardiac centres in Scotland, and is revolutionising cardiac surgery after playing a leading role in realising the world’s first robotic aortic valve replacement through a tiny incision in the neck.
Continued partnership
InnoScot Health has been part of the CardioPrecision journey since its earliest days and has actively invested in its growth and success.
- In 2022, InnoScot Health invested alongside London & Scottish Investment Partners, Discovery Investment Fund and Scottish Enterprise to enable CardioPrecision to begin roll out of its technology post relaxation of international COVID restrictions
- In 2023, CardioPrecision introduced its unique technology for use in Endoscopic Vein Harvesting (EVH) during coronary artery bypass grafting (CABG) surgery at the prestigious Massachusetts General Hospital in Boston
- In 2024, CardioPrecision played a leading role in bringing the world’s first robotic aortic valve replacement through the neck significantly closer to reality. The company demonstrated a proof-of-concept AVATAR (Advanced Videoscopic Aortic valve surgery by Transcervical Approach using Robot-assistance) procedure in Chicago. This represented an important milestone in progressing towards clinical cases, utilising the company’s CoreVista® Robot Enabling Platform™
- In 2025, CardioPrecision further enhanced its reputation after successfully executing the world’s first clinical cases of robotic aortic valve replacement through a precise opening in the neck
Impact
CardioPrecision is dedicated to making patients’ lives better through the development of innovative, less invasive access solutions for cardiothoracic surgery and cardiovascular interventions. With InnoScot Health’s backing, the company continues to go from strength to strength — widening its scope from Scottish success to making its mark on the international map with major robotic surgery breakthroughs.
Supporting those exciting growth aims, InnoScot Health continues to sit on the CardioPrecision board, helping to inform its strategic direction, while publicising milestone progress through national and trade press as well as amplifying across its own channels.
We are in no doubt that our platform technology has incredible potential and the international interest we are receiving bears that out. We will continue to make exciting inroads in the US, from recognition to integration.
Dr Ying Sutherland, CEO, CardioPrecision
Related news
Chat